Active not recruiting
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
I5T-MC-AACG - ClinicalTrials.gov - NCT03367403
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
How long will I be in the trial?
Your participation could last up to 124 weeks and include up to 26 visits to the study center.
Active not recruiting
A Study of LY3002813 in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ)
I5T-MC-AACG - ClinicalTrials.gov - NCT03367403
The purpose of this study is to evaluate the safety, tolerability and efficacy of LY3002813 in early symptomatic Alzheimer's disease.
How long will I be in the trial?
Your participation could last up to 124 weeks and include up to 26 visits to the study center.
Key Requirements
Age :
60-85
Sex:
All
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
60-85
Sex
All
Participants must
Participant must have gradual and progressive change in memory for at least 6 months
Participant must be able to have a positron emission tomography (PET) scan
Participant must be able to have an magnetic resonance imaging (MRI) scan - Participant receiving treatment with one of the symptomatic Alzheimer's drugs must be on a stable dose for at least 2 months
Participant must have a reliable study partner with whom they live or have regular contact (at least 10 hours of communication each week), and who can come to study visits
Participants must NOT
Trial Summary
Conditions the trial is for
Early Symptoms of Alzheimer's Disease
What the trial is testing?
LY3002813, Placebo (IV),
Could I receive a Placebo?
yes
Enrollment Goal
266
Trial Dates
December 2017 - November 2021
Trial Phase
2
Enter your postal code to find the nearest site
Key Requirements
Use the following checklist to help determine if this trial may be a good fit for you. Place a checkmark next to each criteria that you successfully meet.
Age
60-85
Sex
All
Participants must
Participant must have gradual and progressive change in memory for at least 6 months
Participant must be able to have a positron emission tomography (PET) scan
Participant must be able to have an magnetic resonance imaging (MRI) scan - Participant receiving treatment with one of the symptomatic Alzheimer's drugs must be on a stable dose for at least 2 months
Participant must have a reliable study partner with whom they live or have regular contact (at least 10 hours of communication each week), and who can come to study visits
Participants must NOT
Trial Summary
Conditions the trial is for
Early Symptoms of Alzheimer's Disease
What the trial is testing?
LY3002813, Placebo (IV),
Could I receive a Placebo?
yes
Enrollment Goal
266
Trial Dates
December 2017 - November 2021
Trial Phase
2
Not the right fit? Sign up to receive updates on new Early Symptoms of Alzheimer's Disease trials.
Trial Locations
Hide locations not currently recruiting
Enter your postal code to see sites near you
Early Symptoms of Alzheimer's Disease Resources
